Clinical Trials Logo

Rhinitis, Allergic clinical trials

View clinical trials related to Rhinitis, Allergic.

Filter by:

NCT ID: NCT01586091 Completed - Allergic Rhinitis Clinical Trials

Safety Study of Levocetirizine and Fexofenadine

LAWAF
Start date: February 2011
Phase: Phase 4
Study type: Interventional

This Study is to comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once daily with Fexofenadine 60 mg twice daily in the histamine induced wheal, flare and itch Response.

NCT ID: NCT01578278 Completed - Clinical trials for Seasonal Allergic Rhinitis

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

Start date: December 2011
Phase: Phase 2
Study type: Interventional

This is a clinical study to evaluate the safety and efficacy of a bepotastine besilate-corticosteroid combination nasal spray for the treatment of seasonal allergic rhinitis (SAR) in an open exposure study with subjects who have a demonstrated history of Mountain Cedar pollen allergy. The primary study objective is to assess the reduction from baseline in averaged morning (AM) and evening (PM) values of reflective total nasal symptom scores for each of 3 nasal sprays (bepotastine besilate-fluticasone propionate combination nasal spray, bepotastine besilate nasal spray, fluticasone propionate nasal spray) compared to placebo nasal spray. For enrolled subjects, the study will involve a 7-10 day run-in screening period dosing with placebo nasal spray and then a 14-day treatment period where subjects will dose twice a day with 1 of the 4 test agent nasal sprays and record reflective and instantaneous scores for both nasal and ocular symptoms prior to each dosing.

NCT ID: NCT01553110 Completed - Allergic Rhinitis Clinical Trials

An Observational Study to Evaluate The Relationship of Nasal Mucus Properties and Symptoms

Start date: March 2012
Phase:
Study type: Observational

This is a study to learn more about the common cold from studying the nasal secretions produced during a cold or episode of allergic rhinitis.

NCT ID: NCT01550471 Completed - Asthma Clinical Trials

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

Start date: March 2012
Phase: Phase 4
Study type: Interventional

This study will provide the clinicians guidance on the safest combination of inhaled and nasal corticosteroids for children with mild asthma and allergic rhinitis respectively; however, one safety concern is that these products are independently known to have dose-related effects on short term and intermediate term growth. Knemometry is a non invasive technique for measuring short-term lower leg growth in children and is currently the method of choice in growth studies of short duration. Subjects will be seen on a weekly basis for 18 weeks and at each visit, lower leg length will be measured using knemometry.

NCT ID: NCT01529229 Completed - Allergic Rhinitis Clinical Trials

Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment

Start date: November 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the treatment of Moderate - Severe Persistent Allergic Rhinitis.

NCT ID: NCT01506843 Completed - Allergic Rhinitis Clinical Trials

Sublingual Immunotherapy in Children With Allergic Rhinitis

SLIT
Start date: October 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the clinical efficacy and mucosal/systemic antibody response changes after SLIT using house dust mite allergen with or without bacterial extracts in mite-allergic children.

NCT ID: NCT01489293 Completed - Asthma Clinical Trials

Inhibitory Receptors in Eosinophils of Atopic Subjects

Start date: May 1, 2012
Phase:
Study type: Observational

The purpose of this study is to analyze the expression and activity of inhibitory molecules on eosinophils obtained from allergic subjects.

NCT ID: NCT01484119 Completed - Clinical trials for Seasonal Allergic Rhinitis

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

SAR
Start date: December 2011
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy and safety of ACT-129968 in adolescent, adult and elderly patients with seasonal allergic rhinitis, due to mountain cedar pollen.

NCT ID: NCT01480271 Completed - Clinical trials for Rhinitis, Allergic, Seasonal

An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.

Start date: May 30, 2011
Phase: Phase 1
Study type: Interventional

GSK2245035 is a highly selective Toll-like Receptor 7(TLR7) agonist capable of preferentially inducing the production of interferon alpha (IFNα) versus tumor necrosis factor alpha (TNFα). The aim of this FTIH study is to collect tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) information to enable the identification of appropriate safe doses of intranasal (i.n) GSK2245035, associated with up-regulation of TLR7-mediated genes in the nasal milieu, for use in subsequent clinical drug development studies. There will be two parts to the study: Healthy Volunteers will be dosed in escalating single doses in Part 1, followed by Allergic Rhinitis (AR) subjects dosed similarly in Part 2.

NCT ID: NCT01439815 Completed - Allergic Rhinitis Clinical Trials

An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo

Start date: September 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the onset of action of fluticasone propionate nasal spray compared to placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube (ABC) after up to 14 days of at home dosing.